CytomX Therapeutics (CTMX) Equity Ratio (2014 - 2026)

CytomX Therapeutics has reported Equity Ratio for 13 years, with the latest figure at 0.89 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 250.09% year-over-year to 0.89; the trailing twelve-month figure through Mar 2026 stood at 0.89 (up 250.09% YoY), and the FY2025 full-year result was 0.65, up 17366.71% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.89, up from 0.65 in the prior quarter.
• The five-year high for Equity Ratio was 0.89 in Q1 2026, with the low at 0.41 in Q2 2023.
• Historically, Equity Ratio has averaged 0.02 across 5 years, with a median of 0.17 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio plunged 24204.87% — and 2025, when it jumped 17366.71%.
• CytomX Therapeutics' Equity Ratio stood at 0.33 in 2022, then increased by 28.46% to 0.24 in 2023, then jumped by 98.39% to 0.0 in 2024, then jumped by 17366.71% to 0.65 in 2025, then soared by 36.29% to 0.89 in 2026.
• The last three Equity Ratio figures came in at 0.89 (Q1 2026), 0.65 (Q4 2025), and 0.68 (Q3 2025), per Business Quant data.